Orally Administered Lenalidomide (CC-5013) Is Anti-angiogenic In ...

Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard Save Email Send to

• Clipboard
• My Bibliography
• Collections
• Citation manager

Display options Display options Format Abstract PubMed PMID

Save citation to file

Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel

Email citation

Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel

Add to Collections

• Create a new collection
• Add to an existing collection

Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Please try again Add Cancel

Add to My Bibliography

• My Bibliography

Unable to load your delegates due to an error Please try again Add Cancel

Your saved search

Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons

• Yes
• No

Email: (change) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel

Create a file for external citation management software

Create file Cancel

Your RSS Feed

Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy

Full text links

Elsevier Science Full text links

Actions

CiteCollectionsAdd to Collections

• Create a new collection
• Add to an existing collection

Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an errorPlease try again Add Cancel PermalinkPermalinkCopyDisplay options Display options Format AbstractPubMedPMID

Page navigation

• Title & authors
• Abstract
• Publication types
• MeSH terms
• Substances
• LinkOut - more resources

Title & authors Abstract Publication types MeSH terms Substances LinkOut - more resources Full text links CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

The thalidomide analogue and immunomodulatory drug (IMiD) lenalidomide (CC-5013, REVLIMID) is emerging as a useful treatment for a number of cancers and has recently entered phase III trials for multiple myeloma. It has been suggested that the anti-tumor effect of lenalidomide is related to its anti-angiogenic potency. In this regard, we have previously shown that lenalidomide inhibits angiogenesis in both rat and human in vitro models but does not affect endothelial cell proliferation. We now show that oral administration of lenalidomide attenuates growth factor-induced angiogenesis in vivo; the rat mesenteric window assay was utilized to show that lenalidomide significantly inhibits vascularization in a dose-dependent manner. We also found that lenalidomide significantly inhibits growth factor-induced endothelial cell migration. This correlates with the inhibitory effect of lenalidomide on growth factor-induced Akt phosphorylation, thereby providing a potential mechanism for its anti-migratory and subsequent anti-angiogenic effects. These data further support the use of lenalidomide as an orally administered drug for the effective treatment of angiogenesis-dependent conditions, including cancer, and suggest a potential mechanism of action.

PubMed Disclaimer

Publication types

• Research Support, Non-U.S. Gov't Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

MeSH terms

• Administration, Oral Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Angiogenesis Inhibitors / pharmacology* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Animals Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Area Under Curve Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Cell Movement / drug effects* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Dose-Response Relationship, Drug Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Endothelium, Vascular / cytology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Endothelium, Vascular / drug effects* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Humans Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Kinetics Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lenalidomide Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Male Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Mesentery / blood supply Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Mesentery / cytology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Phosphorylation / drug effects Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Protein Serine-Threonine Kinases / metabolism* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Proto-Oncogene Proteins / metabolism* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Proto-Oncogene Proteins c-akt Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Rats Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Rats, Sprague-Dawley Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Thalidomide / administration & dosage* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Thalidomide / analogs & derivatives* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Thalidomide / pharmacokinetics Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Thalidomide / pharmacology* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Umbilical Veins / cytology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Substances

• Angiogenesis Inhibitors Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Proto-Oncogene Proteins Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Thalidomide Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• AKT1 protein, human Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Akt1 protein, rat Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Protein Serine-Threonine Kinases Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Proto-Oncogene Proteins c-akt Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lenalidomide Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • ClinicalTrials.gov

• Miscellaneous

  • NCI CPTAC Assay Portal

Full text links [x] Elsevier Science [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM Send To

• Clipboard
• Email
• Save
• My Bibliography
• Collections
• Citation Manager

[x]

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.